Blood interleukin 12 as preoperative predictor of fatal postoperative sepsis after neoadjuvant radiochemotherapy

British Journal of Surgery

Volumn 93, Issue 10, 2006, Pages 1283-1289

  Novotny, A R ^a   Emmanuel, K ^a   Ulm, K ^b   Battels, H ^a   Siewert, J R ^a   Weighardt, H ^a   Holzmann, B ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 12;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PEROPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; SURGICAL MORTALITY; SURGICAL TECHNIQUE;

BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS;

EID: 33749624901     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5404     Document Type: Article

References (29)

1. Weighardt H, Heidecke C-D, Westerholt A, Emmanuilidis K, Maier S, Veit M et al. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 2002; 235: 560-567.
2. Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998; 85: 840-844.
3. Gagner M. Value of preoperative physiologic assessment in outcome of patients undergoing major surgical procedures. Surg Clin North Am 1991; 71: 1141-1150.
4. Arvidsson S, Ouchterlony J, Sjostedt L, Svardsudd K. Predicting postoperative adverse events. Clinical efficiency of four general classification systems. The project perioperative risk. Acta Anaesthesiol Scand 1996; 40: 783-791.
5. Hensler T, Heidecke C-D, Hecker H, Heeg K, Bartels H, Zantl N et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J Immunol 1998; 161: 2655-2659.
6. Steinhauser ML, Hogaboam CM, Lukacs NW, Stricter RM, Kunkel SL. Multiple roles for IL-12 in a model of acute septic peritonitis. J Immunol 1999; 162: 5437-5443.
7. Zantl N, Uebe A, Neumann B, Wagner H, Siewert J-R, Holzmann B et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 1998; 66: 2300-2309.
8. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997; 8: 349-356.
9. Goebel A, Kavanagh E, Lyons A, Saporoschetz IB, Soberg C, Lederer JA et al. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann Surg 2000; 231: 253-261.
10. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995; 222: 482-492.
11. Haraguchi S, Day NK, Nelson RP Jr, Emmanuel P, Duplantier JE, Christodoulou CS et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A 1998; 95: 13 125-13 129.
12. Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 1998; 102: 2035-2040.
13. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-276.
14. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996; 17: 214-217.
15. Heidecke C-D, Weighardt H, Feith M, Fink U, Zimmermann F, Stein HJ et al. Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy. Surgery 2002; 132: 495-501.
16. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004; 8: R291-R298.
17. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
18. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993; 7: 771-793.
19. Allegretta GJ, Weisman SJ, Altman AJ. Oncologic emergencies II. Hematologic and infectious complications of cancer and cancer treatment. Pediatr Clin North Am 1985; 32: 613-624.
20. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley: New York, 1989.
22. Breimann L, Friedmann JH, Olshen RA, Stone CJ. Classification and Regression Trees. Wadsworth: Belmont, 1984.
23. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521.
24. Wolters U, Bollschweiler E, Ekkernkamp A, Holscher AH. Risk evaluation in German clinics. Results of a survey. Chirurg 2002; 73: 1205-1212.
25. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2000; 48: 997-1006.
26. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolatyngol Head Neck Surg 1998; 119: 412-417.
27. Vuckovic-Dekic L, Susnjar S, Stanojevic-Bakic N, Radosavljevic D. Radio- and chemotherapy variably affect the general immunocompetence of lung cancer patients. Panminerva Med 1999; 41: 129-133.
28. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
29. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210-217.